Wellington Management Group LLP Has $13.28 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

Wellington Management Group LLP lifted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 352.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,096,744 shares of the company's stock after purchasing an additional 854,346 shares during the period. Wellington Management Group LLP owned about 1.60% of Replimune Group worth $13,282,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REPL. Sei Investments Co. acquired a new stake in shares of Replimune Group in the fourth quarter valued at approximately $148,000. KLP Kapitalforvaltning AS purchased a new position in Replimune Group in the 4th quarter valued at $150,000. Arizona State Retirement System purchased a new stake in shares of Replimune Group in the fourth quarter valued at about $156,000. BNP Paribas Financial Markets increased its position in Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock worth $165,000 after purchasing an additional 6,748 shares during the period. Finally, Teacher Retirement System of Texas purchased a new position in Replimune Group in the fourth quarter worth $189,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on REPL shares. BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Replimune Group has a consensus rating of "Buy" and a consensus target price of $19.43.

Remove Ads

Replimune Group Price Performance

Replimune Group stock traded up $0.29 during trading hours on Tuesday, hitting $7.80. 217,407 shares of the company traded hands, compared to its average volume of 865,375. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a market cap of $601.03 million, a P/E ratio of -2.54 and a beta of 1.26. The firm's 50-day simple moving average is $11.21 and its two-hundred day simple moving average is $11.86.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.